PARK7 and cardiovascular disorder: Therefore, Cu(II)ATSM represents a novel Nrf2 and DJ-1 activator with therapeutic potential to enhance endogenous antioxidant defenses, providing protection against cardiovascular diseases through ameliorating oxidative stress.